RESUMEN
INTRODUCTION: Hospitalised older patients frequently suffer from inadequate sleep, which can lead to patient distress and delayed recovery from acute illness or surgical procedure. Currently, no evidence-based treatments exist for sleeping problems in hospitalised older patients. Benzodiazepines, such as temazepam, are regularly prescribed by physicians, although they have serious side effects; for older patients in particular. Melatonin is proposed as a safe alternative for sleeping problems in hospitalised older patients, but the efficacy of melatonin is unclear in this population. Therefore, the aim of this study is to investigate the effects of melatonin and temazepam compared with placebo on sleep quality among hospitalised older patients with sleeping problems. METHODS AND ANALYSIS: This study is a multicentre, randomised, placebo-controlled trial. A total of 663 patients will be randomised in a 1:1:1 fashion to receive either melatonin (n=221), temazepam (n=221) or placebo (n=221). The study population consists of hospitalised patients aged 60 years and older, with new or aggravated sleeping problems for which an intervention is needed. The primary outcome is sleep quality measured with the Leeds Sleep Evaluation Questionnaire (LSEQ). Secondary outcomes include sleep parameters measured with actigraphy and medication-related adverse effects. ETHICS AND DISSEMINATION: This study was approved by the Medical Ethics Committee of the Academic Medical Centre Amsterdam, (No 2015_302). Study findings will be disseminated through presentations at professional and scientific conferences and publications in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NTR6908; Pre-results.
Asunto(s)
Preparaciones de Acción Retardada/uso terapéutico , Geriatría , Hipnóticos y Sedantes/uso terapéutico , Melatonina/uso terapéutico , Trastornos del Sueño-Vigilia/tratamiento farmacológico , Temazepam/uso terapéutico , Anciano , Nivel de Alerta/efectos de los fármacos , Preparaciones de Acción Retardada/farmacología , Hospitalización , Humanos , Hipnóticos y Sedantes/farmacología , Melatonina/farmacología , Persona de Mediana Edad , Placebos , Ensayos Clínicos Controlados Aleatorios como Asunto , Sueño/efectos de los fármacos , Temazepam/farmacología , Resultado del TratamientoAsunto(s)
Baclofeno/efectos adversos , Problema de Conducta/psicología , Síndrome de Abstinencia a Sustancias/complicaciones , Adulto , Antipsicóticos/farmacología , Antipsicóticos/uso terapéutico , Baclofeno/uso terapéutico , Benzodiazepinas/farmacología , Benzodiazepinas/uso terapéutico , Diazepam/farmacología , Diazepam/uso terapéutico , Droperidol/farmacología , Droperidol/uso terapéutico , Humanos , Masculino , Convulsiones/tratamiento farmacológico , Convulsiones/etiología , Temazepam/farmacología , Temazepam/uso terapéuticoRESUMEN
BACKGROUND: Electronic prescription registers provide a vast data source for pharmacoepidemiological research. Prescriptions as such are not suitable for all research purposes; e.g., studying concurrent use of different drugs or adverse drug events during current use. For those purposes, data on dispensed prescriptions needs to be transformed to periods of drug use. METHODS: We used 3,828,292 dispensed prescriptions claimed between 1 January 2002 and 31 December 2009 for 28,093 persons with Alzheimer's disease. Examples of drug use histories are presented to discuss different aspects that should be noticed when using register-based data consisting of drug purchases. RESULTS: There is no simple method for correctly transforming dispensed prescriptions to periods of drug use that is usable for all drugs and drug users. Fixed assumptions of daily dose (in defined daily doses, tablets or other units) and fixed time windows should be used with caution and adjusted for different drug use patterns. CONCLUSIONS: We recommend that when transforming prescription drug purchases to drug use periods personal dose, purchasing pattern and other behavioral differences between patients should be taken into account.
Asunto(s)
Prescripciones de Medicamentos , Preparaciones Farmacéuticas , Enfermedad de Alzheimer/tratamiento farmacológico , Citalopram/uso terapéutico , Diuréticos/uso terapéutico , Relación Dosis-Respuesta a Droga , Etiquetado de Medicamentos , Humanos , Losartán/uso terapéutico , Metoprolol/uso terapéutico , Comprimidos , Temazepam/uso terapéutico , Factores de TiempoRESUMEN
BACKGROUND: Post-traumatic stress disorder (PTSD) is a debilitating disorder which, after a sufficient delay, may be diagnosed amongst individuals who respond with intense fear, helplessness or horror to traumatic events. There is some evidence that the use of pharmacological interventions immediately after exposure to trauma may reduce the risk of developing of PTSD. OBJECTIVES: To assess the effects of pharmacological interventions for the prevention of PTSD in adults following exposure to a traumatic event. SEARCH METHODS: We searched the Cochrane Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR-Studies and CCDANCTR-References) (to 14 February 2014). This register contains relevant reports of randomised controlled trials from the following bibliographic databases: CENTRAL (all years); EMBASE (1974 to date); MEDLINE (1950 to date) and PsycINFO (1967 to date). We identified unpublished trials by searching the National Institute of Health (NIH) Reporter, the metaRegister of Controlled Trials database (mRCT) and the WHO International Clinical Trials Registry Platform (to December 2013). We scanned the reference lists of articles for additional studies. We placed no constraints on language and setting. SELECTION CRITERIA: We restricted studies to randomised controlled trials (RCTs) of pharmacological interventions compared with placebo for the prevention of PTSD in adults. DATA COLLECTION AND ANALYSIS: Two authors (TA and JI) independently assessed trials for eligibility and inclusion based on the review selection criteria. We independently extracted sample, methodological, outcome and 'Risk of bias' data, as well as the number of side effects, from each trial and entered these into a customised data extraction form. We contacted investigators for missing information. We calculated summary statistics for continuous and dichotomous variables (if provided). We did not undertake subgroup analyses due to the small number of included studies. MAIN RESULTS: We included nine short-term RCTs (duration 12 weeks or less) in the analysis (345 participants; age range 18 to 76 years). Participants were exposed to a variety of traumas, ranging from assault, traffic accidents and work accidents to cardiac surgery and septic shock. Seven studies were conducted at single centres. The seven RCTs included four hydrocortisone studies, three propranolol studies (of which one study had a third arm investigating gabapentin), and single trials of escitalopram and temazepam. Outcome assessment measures included the Clinician-Administered PTSD Scale (CAPS), the 36-Item Short-Form Health Survey (SF-36) and the Center for Epidemiological Studies - Depression Scale (CES-D).In four trials with 165 participants there was moderate quality evidence for the efficacy of hydrocortisone in preventing the onset of PTSD (risk ratio (RR) 0.17; 95% confidence interval (CI) 0.05 to 0.56; P value = 0.004), indicating that between seven and 13 patients would need to be treated with this agent in order to prevent the onset of PTSD in one patient. There was low quality evidence for preventing the onset of PTSD in three trials with 118 participants treated with propranolol (RR 0.62; 95% CI 0.24 to 1.59; P value = 0.32). Drop-outs due to treatment-emergent side effects, where reported, were low for all of the agents tested. Three of the four RCTs of hydrocortisone reported that medication was more effective than placebo in reducing PTSD symptoms after a median of 4.5 months after the event. None of the single trials of escitalopram, temazepam and gabapentin demonstrated evidence that medication was superior to placebo in preventing the onset of PTSD.Seven of the included RCTs were at a high risk of bias. Differential drop-outs between groups undermined the results of three studies, while one study failed to describe how the allocation of medication was concealed. Other forms of bias that might have influenced study results included possible confounding through group differences in concurrent medication and termination of the study based on treatment response. AUTHORS' CONCLUSIONS: There is moderate quality evidence for the efficacy of hydrocortisone for the prevention of PTSD development in adults. We found no evidence to support the efficacy of propranolol, escitalopram, temazepam and gabapentin in preventing PTSD onset. The findings, however, are based on a few small studies with multiple limitations. Further research is necessary in order to determine the efficacy of pharmacotherapy in preventing PTSD and to identify potential moderators of treatment effect.
Asunto(s)
Trastornos por Estrés Postraumático/prevención & control , Antagonistas de Receptores Adrenérgicos beta 1/uso terapéutico , Adulto , Anciano , Aminas/uso terapéutico , Ansiolíticos/uso terapéutico , Antiinflamatorios/uso terapéutico , Antidepresivos de Segunda Generación/uso terapéutico , Citalopram/uso terapéutico , Ácidos Ciclohexanocarboxílicos/uso terapéutico , Gabapentina , Humanos , Hidrocortisona/uso terapéutico , Persona de Mediana Edad , Propranolol/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Temazepam/uso terapéutico , Adulto Joven , Ácido gamma-Aminobutírico/uso terapéuticoRESUMEN
The basic techniques of conscious sedation have been found to be safe and effective for the management of anxiety in adult dental patients requiring sedation to allow them to undergo dental treatment. There remains great debate within the profession as to the role of the so called advanced sedation techniques. This paper presents a series of nine patients who were managed with advanced sedation techniques where the basic techniques were either inappropriate or had previously failed to provide adequate relief of anxiety. In these cases, had there not been the availability of advanced sedation techniques, the most likely recourse would have been general anaesthesia--a treatment modality that current guidance indicates should not be used where there is an appropriate alternative. The sedation techniques used have provided that appropriate alternative management strategy.
Asunto(s)
Anestesia Dental/métodos , Sedación Consciente/métodos , Adolescente , Adulto , Analgésicos Opioides/administración & dosificación , Anestesia Intravenosa/métodos , Anestésicos Combinados/administración & dosificación , Anestésicos Intravenosos/administración & dosificación , Ansiolíticos/uso terapéutico , Ansiedad al Tratamiento Odontológico/prevención & control , Femenino , Humanos , Hipnóticos y Sedantes/administración & dosificación , Masculino , Midazolam/administración & dosificación , Persona de Mediana Edad , Propofol/administración & dosificación , Temazepam/uso terapéuticoRESUMEN
This study is the first comparative trial of sleep medications at high altitude. We performed a randomized, double-blind trial of temazepam and acetazolamide at an altitude of 3540 meters. 34 healthy trekkers with self-reports of high-altitude sleep disturbance were randomized to temazepam 7.5 mg or acetazolamide 125 mg taken at bedtime for one night. The primary outcome was sleep quality on a 100 mm visual analog scale. Additional measurements were obtained with actigraphy; pulse oximetry; and questionnaire evaluation of sleep, daytime drowsiness, daytime sleepiness, and acute mountain sickness. Sixteen subjects were randomized to temazepam and 18 to acetazolamide. Sleep quality on the 100 mm visual analog scale was higher for temazepam (59.6, SD 20.1) than acetazolamide (46.2, SD 20.2; p=0.048). Temazepam also demonstrated higher subjective sleep quality on the Groningen Sleep Quality Scale (3.5 vs. 6.8, p=0.009) and sleep depth visual analog scale (60.3 vs. 41.4, p=0.028). The acetazolamide group reported significantly more awakenings to urinate (1.8 vs. 0.5, p=0.007). No difference was found with regards to mean nocturnal oxygen saturation (84.1 vs. 84.4, p=0.57), proportion of the night spent in periodic breathing, relative desaturations, sleep onset latency, awakenings, wake after sleep onset, sleep efficiency, Stanford Sleepiness Scale scores, daytime drowsiness, or change in self-reported Lake Louise Acute Mountain Sickness scores. We conclude that, at current recommended dosing, treatment of high-altitude sleep disturbance with temazepam is associated with increased subjective sleep quality compared to acetazolamide.
Asunto(s)
Acetazolamida/uso terapéutico , Altitud , Inhibidores de Anhidrasa Carbónica/uso terapéutico , Hipnóticos y Sedantes/uso terapéutico , Trastornos Intrínsecos del Sueño/tratamiento farmacológico , Temazepam/uso terapéutico , Actigrafía , Adulto , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Oxígeno/sangre , Trastornos Intrínsecos del Sueño/sangre , Fases del Sueño/efectos de los fármacos , Encuestas y Cuestionarios , Adulto JovenRESUMEN
Narcolepsy is characterized by fragmented nighttime sleep and frequent arousals. One treatment approach to improve daytime symptoms is to consolidate nighttime sleep through decreasing arousals. Sodium oxybate is the first FDA-approved medication that follows this approach. Benzodiazepines are known to also decrease arousals at night and have been proposed to help with sleep fragmentation. In one report, clonazepam was shown to improve cataplexy in 10 of 14 patients with narcolepsy although no improvement in daytime sleepiness was reported. The purpose of this case review was to share our experience of nocturnal temazepam on daytime sleepiness in patients with narcolepsy as measured by the Epworth Sleepiness Scale (ESS).
Asunto(s)
Hipnóticos y Sedantes/uso terapéutico , Narcolepsia/tratamiento farmacológico , Temazepam/uso terapéutico , Adolescente , Adulto , Anciano , Niño , Esquema de Medicación , Humanos , Hipnóticos y Sedantes/administración & dosificación , Persona de Mediana Edad , Polisomnografía/métodos , Estudios Retrospectivos , Temazepam/administración & dosificación , Resultado del Tratamiento , Adulto JovenRESUMEN
OBJECTIVE: The objective of this article is to examine patterns of temazepam prescribing amongst inpatients at a Sydney teaching hospital. METHOD: The study involved a retrospective file audit of 98.8% (n=410) of patients discharged from psychiatry, medical, surgical and obstetric and gynaecology wards of Nepean Hospital during a one-week period. Data was collected on patient demographics, temazepam and other sedative-hypnotic use, falls risk and analgesia use. RESULTS: Sixteen per cent (n=64) of patients were prescribed temazepam during their stay. All patients from the psychiatry wards had been prescribed temazepam. Fifteen per cent (n=6) of falls risk patients had been prescribed temazepam. Temazepam prescription was associated with an increased length of stay, psychiatry and surgical wards, and higher use of analgesia. CONCLUSIONS: Temazepam continues to be a frequently prescribed medication in the acute psychiatry setting. Its frequent prescription to patients in surgical wards and to those prescribed analgesic agents indicates that it still has a role in settling patients to sleep in the hospital setting.
Asunto(s)
Accidentes por Caídas , Hipnóticos y Sedantes/uso terapéutico , Pautas de la Práctica en Medicina/estadística & datos numéricos , Trastornos del Sueño-Vigilia/tratamiento farmacológico , Temazepam/uso terapéutico , Adulto , Anciano , Analgésicos/uso terapéutico , Femenino , Hospitales de Enseñanza , Humanos , Pacientes Internos/estadística & datos numéricos , Tiempo de Internación , Masculino , Persona de Mediana Edad , Nueva Gales del Sur , Estudios RetrospectivosAsunto(s)
Anticonvulsivantes/uso terapéutico , Clonazepam/uso terapéutico , Hipnóticos y Sedantes/uso terapéutico , Síndrome de Mioclonía Nocturna/tratamiento farmacológico , Temazepam/uso terapéutico , Analgésicos Opioides/uso terapéutico , Ensayos Clínicos como Asunto , Dopaminérgicos/uso terapéutico , Agonistas de Dopamina/uso terapéutico , Humanos , Guías de Práctica Clínica como Asunto , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del TratamientoRESUMEN
Centrally active agents have a variable impact in patients with obstructive sleep apnoea (OSA) that is unexplained. How to phenotype the individual OSA response is clinically important, as it may help to identify who will be at risk of respiratory depression and who will benefit from a centrally active agent. Based on loop gain theory, we hypothesized that OSA patients with higher central chemosensitivity have higher breathing instability following the use of a hypnosedative, temazepam. In 20 men with OSA in a double-blind, placebo-controlled cross-over trial we tested the polysomnographically (PSG) measured effects of temazepam 10 mg versus placebo on sleep apnoea. Treatment nights were at least 1 week apart. Ventilatory chemoreflexes were also measured during wakefulness in each subject. The patients (mean ± standard deviation; 44 ± 12 years) had predominantly mild-to-moderate OSA [baseline apnoea-hypopnoea index (AHI) = 16.8 ± 14.1]. Patients' baseline awake central chemosensitivity correlated significantly with both the change of SpO2 nadir between temazepam and placebo (r = -0.468, P = 0.038) and oxygen desaturation index (ODI; r = 0.485, P = 0.03), but not with the change of AHI (r = 0.18, P = 0.44). Peripheral chemosensitivity and ventilatory recruitment threshold were not correlated with the change of SpO2 nadir, ODI or AHI (all P > 0.05). Mild-moderate OSA patients with higher awake central chemosensitivity had greater respiratory impairment during sleep with temazepam. Relatively simple daytime tests of respiratory control may provide a method of determining the effect of sedative-hypnotic medication on breathing during sleep in OSA patients.
Asunto(s)
Hipnóticos y Sedantes/uso terapéutico , Respiración/efectos de los fármacos , Apnea Obstructiva del Sueño/tratamiento farmacológico , Temazepam/uso terapéutico , Vigilia/fisiología , Adulto , Estudios Cruzados , Método Doble Ciego , Humanos , Masculino , Fenotipo , Polisomnografía , Sueño/efectos de los fármacos , Sueño/fisiología , Apnea Obstructiva del Sueño/fisiopatologíaAsunto(s)
Anestesia Dental/métodos , Competencia Clínica , Sedación Consciente/métodos , Hipnóticos y Sedantes/uso terapéutico , Premedicación/métodos , Temazepam/uso terapéutico , Anestesia Dental/normas , Sedación Consciente/normas , Humanos , Pautas de la Práctica en Odontología/normas , Premedicación/normasRESUMEN
BACKGROUND: Benzodiazepines can improve sleep quality, but are also thought to cause respiratory depression in patients with chronic obstructive pulmonary disease (COPD). The aims of this study were to assess the effects of temazepam on indices of circadian respiratory function, dyspnea, sleep quality, and sleepiness in patients with severe COPD and insomnia. METHODS: In a double-blind, randomized, placebo-controlled, cross-over study in 14 stable patients with COPD (mean FEV(1) 0.99+/-0.3L) with insomnia, polysomnography with continuous transcutaneous capnography and oximetry, arterial gas sampling, hypercapnic ventilatory response, multiple sleep latency test, Epworth Sleepiness Scale, dyspnea and sleep visual analogue scales (VAS) were performed at baseline, after one week of temazepam 10mg at bedtime and after one week of placebo. RESULTS: Temazepam did not cause statistically significant changes in mean transcutaneous carbon dioxide tension during sleep compared to placebo (5.9+/-1.0 kPa vs. 6.3+/-1.4 kPa, p-value 0.27), nor in mean oxygen saturation (92+/-3% vs. 92+/-2%, p-value 0.31), nor in any of the other investigated variables, except for the total sleep time and sleep latency VAS, which improved with temazepam. CONCLUSIONS: One week usage of temazepam 10mg does not influence circadian respiratory function, dyspnea, and sleepiness in patients with stable, severe, normocapnic COPD and insomnia and it improves total sleep time and subjective sleep latency. However, this is a preliminary explorative study for assessing the feasibility to perform a larger study on this topic. The clinical implications of this study are very limited.
Asunto(s)
Disnea/tratamiento farmacológico , Hipnóticos y Sedantes/uso terapéutico , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Intercambio Gaseoso Pulmonar/efectos de los fármacos , Síndromes de la Apnea del Sueño/tratamiento farmacológico , Temazepam/uso terapéutico , Estudios Cruzados , Método Doble Ciego , Femenino , Humanos , Hipercapnia/tratamiento farmacológico , Hipercapnia/fisiopatología , Masculino , Persona de Mediana Edad , Países Bajos , Oximetría , Polisomnografía , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Intercambio Gaseoso Pulmonar/fisiología , Síndromes de la Apnea del Sueño/fisiopatología , Resultado del TratamientoRESUMEN
Panic disorder still remains a pervasive, life quality impairing disorder requiring adequate treatment options. In this case report we present the data of a patient with panic disorder and comorbid depression who was treated with high-frequency repetitive transcranial magnetic stimulation (rTMS) applied to the left prefrontal cortex over a course of 3 weeks. Measurements of the cerebral oxygenation with near-infrared spectroscopy (NIRS) during an emotional Stroop task before and after the rTMS treatment suggests that rTMS may modulate panic-related prefrontal brain dysfunctions in panic patients and that it may serve as a possible treatment option for anxiety disorders.
Asunto(s)
Trastorno de Pánico/terapia , Estimulación Magnética Transcraneal/métodos , Inhibidores de Captación Adrenérgica/uso terapéutico , Antagonistas Adrenérgicos alfa/uso terapéutico , Antagonistas Adrenérgicos beta/uso terapéutico , Adulto , Amitriptilina/uso terapéutico , Bisoprolol/uso terapéutico , Terapia Combinada , Quimioterapia Combinada , Moduladores del GABA/uso terapéutico , Humanos , Masculino , Trastorno de Pánico/tratamiento farmacológico , Sulfonamidas/uso terapéutico , Tamsulosina , Temazepam/uso terapéuticoRESUMEN
Given the well-established problems with sleep at high altitude, it is not uncommon for people planning trips to the mountains to seek advice from clinicians regarding pharmacologic options for improving sleep during their trip. This review article considers the various medications that have been studied for this purpose at high altitude with an emphasis on both their efficacy and safety. The available data support the use of either acetazolamide, temazepam, zolpidem or zaleplon in this environment. Other agents commonly used at sea-level such as eszopiclone and diphenhydramine have not been studied at high altitude but are likely safe to use given their mechanism of action and known side effects. Limited evidence suggests diazepam may cause hypoventilation at high altitude and its use in this environment should be discouraged. Insufficient data exist to determine which agent is most effective at altitude nor do we know whether combination therapy with acetazolamide and a hypnotic agent offers any benefits over monotherapy.
Asunto(s)
Mal de Altura/fisiopatología , Ansiolíticos/uso terapéutico , Agonistas del GABA/uso terapéutico , Hipnóticos y Sedantes/uso terapéutico , Montañismo , Trastornos del Inicio y del Mantenimiento del Sueño/tratamiento farmacológico , Acetamidas/uso terapéutico , Acetazolamida/uso terapéutico , Compuestos de Azabiciclo/uso terapéutico , Benzodiazepinas/uso terapéutico , Difenhidramina/uso terapéutico , Eszopiclona , Humanos , Piperazinas/uso terapéutico , Piridinas/uso terapéutico , Pirimidinas/uso terapéutico , Fases del Sueño/efectos de los fármacos , Temazepam/uso terapéutico , Vigilia/efectos de los fármacos , ZolpidemRESUMEN
A randomized, controlled, crossover clinical study compared 14-night treatment with 15 mg temazepam, 50 mg diphenhydramine, and placebo in elderly individuals with insomnia (mean age, 73.9 years; range, 70-89 years). Primary outcome measures were subjective assessments of sleep recorded on sleep diaries. Secondary measures were the morning-after psychomotor impairment, using the digit symbol substitution task and the manual tracking task, and the morning-after memory impairment, using a free-recall procedure. Results showed sleep improvements with 15 mg temazepam compared with placebo-sleep quality (mean score, 3.3 +/- 0.9 vs 2.9 +/- 0.8; P = 0.03), total sleep time (6.9 +/- 1.0 hours vs 6.3 +/-1.3 hours; P = 0.02), number of awakenings (1.5 +/- 1.3 vs 2.0 +/- 1.2; P < 0.001), and sleep-onset latency (25 +/- 22 minutes vs 37 +/- 25 minutes; P = 0.03). Improvements were seen with diphenhydramine treatment compared with placebo on the number of awakenings only (mean, 1.7 +/- 1.1 vs 2.0 +/- 1.2; P < 0.05). Numbers of adverse events reported were similar after all treatments, although there was 1 fall during temazepam treatment. Findings indicate that temazepam is more effective than diphenhydramine when compared with placebo at the doses tested, although this advantage is mitigated by the risk of falls associated with temazepam use. The choice of agent to use in the elderly must consider these relative benefits and risks.
Asunto(s)
Difenhidramina/uso terapéutico , Trastornos del Inicio y del Mantenimiento del Sueño/tratamiento farmacológico , Temazepam/uso terapéutico , Anciano , Anciano de 80 o más Años , Estudios Cruzados , Difenhidramina/efectos adversos , Difenhidramina/sangre , Mareo/inducido químicamente , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Humanos , Hipnóticos y Sedantes/efectos adversos , Hipnóticos y Sedantes/uso terapéutico , Masculino , Náusea/inducido químicamente , Pacientes Desistentes del Tratamiento , Placebos , Sueño/efectos de los fármacos , Trastornos del Inicio y del Mantenimiento del Sueño/fisiopatología , Temazepam/efectos adversos , Temazepam/sangre , Factores de Tiempo , Resultado del TratamientoRESUMEN
AIM: This article describes the current magnetic resonance imaging (MRI) sedation service, the role of the nurse sedationist, results of clinical audits, and future issues within MRI. METHOD: Data from 2004 until 2006 were analysed to describe the percentage of children who were successfully sedated, and any complications. The recovery profile was investigated by a questionnaire of 100 consecutive cases. FINDINGS: Sedation was attempted in 455 cases with chloral hydrate, and 325 with temazepam and droperidol. The success rate was 97.4 and 92.6 per cent respectively. Top-up sedation was used in 10 and 29 per cent respectively. There were seven minor incidents but none required admission. Approximately 20 per cent of children were drowsy the following day. CONCLUSION: We believe that the success of the service depends upon three main factors: the deselection of children in whom sedation is unsafe or likely to be unsuccessful, the use of appropriate drugs in limited doses, and the training of experienced nurses.
Asunto(s)
Sedación Consciente/enfermería , Imagen por Resonancia Magnética/enfermería , Rol de la Enfermera , Enfermería Pediátrica/organización & administración , Adyuvantes Anestésicos/uso terapéutico , Niño , Hidrato de Cloral/uso terapéutico , Protocolos Clínicos , Sedación Consciente/efectos adversos , Sedación Consciente/métodos , Droperidol/uso terapéutico , Monitoreo de Drogas/enfermería , Quimioterapia Combinada , Educación Continua en Enfermería , Humanos , Hipnóticos y Sedantes/uso terapéutico , Capacitación en Servicio , Liderazgo , Londres , Evaluación en Enfermería , Auditoría de Enfermería , Investigación en Evaluación de Enfermería , Alta del Paciente , Enfermería Pediátrica/educación , Autonomía Profesional , Seguridad , Temazepam/uso terapéuticoRESUMEN
The aim of the study was to examine the efficacy and safety of temazepam on nocturnal oxygenation and next-day performance at altitude. A double-blind, randomized, cross-over trial was performed in Thirty-three healthy volunteers. Volunteers took 10 mg of temazepam and placebo in random order on two successive nights soon after arrival at 5000 m, following a 17-day trek from 410 m. Overnight SaO(2) and body movements, and next-day reaction time, maintenance of wakefulness and cognition were assessed. Compared with placebo, temazepam resulted in a reduction in periodic breathing from a median (range) of 16 (0-81.3)% of the night to 9.4 (0-79.6)% (P = 0.016, Wilcoxon's signed-rank test), associated with a small but significant decrease in mean nocturnal SaO(2) from 78 (65-84)% to 76 (64-83)% (P = 0.013). There was no change in sleep latency (P = 0.40) or restlessness (P = 0.30). Temazepam had no adverse effect on next-day reaction time [241 (201-380) ms postplacebo and 242 (204-386) ms post-temazepam], maintenance of wakefulness (seven trekkers failed to maintain 40 min of wakefulness postplacebo, and four post-temazepam), cognition or acute mountain sickness. At high altitude temazepam reduces periodic breathing during sleep without an adverse effect on next-day reaction time, maintenance of wakefulness or cognition. The 2% reduction in mean SaO(2) post-temazepam is likely to be predominantly because of acclimatization, as by chance more trekkers took temazepam on the first night (19 versus 14). We conclude that at high altitude temazepam is effective in reducing periodic breathing, and is safe to use, without any adverse effect upon next-day performance.
Asunto(s)
Mal de Altura/tratamiento farmacológico , Atención/efectos de los fármacos , Hipnóticos y Sedantes/uso terapéutico , Tiempo de Reacción/efectos de los fármacos , Apnea Central del Sueño/tratamiento farmacológico , Temazepam/uso terapéutico , Estudios Cruzados , Método Doble Ciego , Humanos , Montañismo , Nepal , Pruebas Neuropsicológicas , Oxígeno/sangre , Polisomnografía/efectos de los fármacos , Resultado del Tratamiento , Vigilia/efectos de los fármacosRESUMEN
BACKGROUND: Double-blind randomised N-of-1 trials (N-of-1 trials) may help with decisions concerning treatment when there is doubt regarding the effectiveness and suitability of medication for individual patients. The patient is his or her own control, and receives the experimental and the control treatment during several periods of time in random order. Reports of N-of-1 trials are still relatively scarce, and the research methodology is not as firmly established as that of RCTs. Recently, we have conducted two series of N-of-1 trials in general practice. Before, during, and after data-collection, difficulties regarding outcome assessment, analysis of the results, the withdrawal of patients, and the follow-up had to be dealt with. These difficulties are described and our solutions are discussed. DISCUSSION: To prevent or anticipate difficulties in N-of-1 trials, we argue that that it is important to individualize the outcome measures, and to carefully consider the objective, type of randomisation and the analysis. It is recommended to use the same dosages and dosage forms that the patient used before the trial, to start the trial with a run-in period, to formulate both general and individualized decision rules regarding the efficacy of treatment, to adjust treatment policies immediately after the trial, and to provide adequate instructions and support if treatment is adjusted. SUMMARY: Because of the specific characteristics of N-of-1 trials it is difficult to formulate general 'how to do it' guidelines for designing N-of-1 trials. However, when the design of each N-of-1 trial is tailored to the specific characteristics of each individual patient and the underlying medical problem, most difficulties in N-of-1 trials can be prevented or overcome. In this way, N-of-1 trials may be of help when deciding on drug treatment for individual patients.